Merck & Co., Inc. (MRK) Holdings Lifted by Steinberg Global Asset Management

Steinberg Global Asset Management raised its stake in Merck & Co., Inc. (NYSE:MRK) by 24.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 150,623 shares of the company’s stock after buying an additional 30,012 shares during the quarter. Merck & Co., Inc. comprises about 1.2% of Steinberg Global Asset Management’s portfolio, making the stock its 23rd biggest holding. Steinberg Global Asset Management’s holdings in Merck & Co., Inc. were worth $8,476,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRK. NewSquare Capital LLC increased its stake in Merck & Co., Inc. by 728.3% during the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock worth $115,000 after purchasing an additional 13,014 shares during the period. Balentine LLC increased its stake in Merck & Co., Inc. by 1.0% during the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after purchasing an additional 20 shares during the period. WealthTrust Arizona LLC increased its stake in Merck & Co., Inc. by 103.7% during the fourth quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock worth $140,000 after purchasing an additional 1,270 shares during the period. Risk Paradigm Group LLC increased its stake in Merck & Co., Inc. by 748.1% during the second quarter. Risk Paradigm Group LLC now owns 2,256 shares of the company’s stock worth $145,000 after purchasing an additional 1,990 shares during the period. Finally, Acrospire Investment Management LLC increased its stake in Merck & Co., Inc. by 212.5% during the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the company’s stock worth $160,000 after purchasing an additional 1,700 shares during the period. 74.60% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

A number of analysts have issued reports on the stock. Credit Suisse Group cut their price target on shares of Merck & Co., Inc. from $67.00 to $66.00 and set an “outperform” rating on the stock in a research note on Monday, February 5th. Leerink Swann cut their price target on shares of Merck & Co., Inc. from $67.00 to $66.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 14th. ValuEngine lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. BMO Capital Markets set a $65.00 price target on shares of Merck & Co., Inc. and gave the stock an “outperform” rating in a research note on Tuesday, February 13th. Finally, Morgan Stanley upped their target price on shares of Merck & Co., Inc. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $66.35.

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 5,000 shares of the stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $58.00, for a total value of $290,000.00. Following the transaction, the insider now directly owns 101,484 shares in the company, valued at $5,886,072. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $3,697,800.00. Following the completion of the transaction, the insider now owns 101,484 shares in the company, valued at $6,254,458.92. The disclosure for this sale can be found here. Insiders sold 82,500 shares of company stock worth $5,026,025 over the last quarter. 0.25% of the stock is currently owned by insiders.

Merck & Co., Inc. stock opened at $53.41 on Friday. The company has a market cap of $144,003.50, a P/E ratio of 13.42, a price-to-earnings-growth ratio of 2.25 and a beta of 0.81. Merck & Co., Inc. has a one year low of $53.12 and a one year high of $66.41. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, February 2nd. The company reported $0.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.04. The company had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.89 earnings per share. equities research analysts anticipate that Merck & Co., Inc. will post 4.17 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 6th. Shareholders of record on Thursday, March 15th will be paid a $0.48 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $1.92 annualized dividend and a yield of 3.59%. Merck & Co., Inc.’s dividend payout ratio is currently 206.45%.

Merck & Co., Inc. declared that its Board of Directors has approved a stock buyback plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

WARNING: “Merck & Co., Inc. (MRK) Holdings Lifted by Steinberg Global Asset Management” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299247/merck-co-inc-mrk-holdings-lifted-by-steinberg-global-asset-management.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mineum  Achieves Market Cap of $283,900.00
Mineum Achieves Market Cap of $283,900.00
MagicCoin  Trading Down 12.9% Over Last Week
MagicCoin Trading Down 12.9% Over Last Week
Financial Comparison: Hologic  vs. Check Cap
Financial Comparison: Hologic vs. Check Cap
Cubic  Lowered to “Strong Sell” at Zacks Investment Research
Cubic Lowered to “Strong Sell” at Zacks Investment Research
$4.67 EPS Expected for Goldman Sachs  This Quarter
$4.67 EPS Expected for Goldman Sachs This Quarter
Verastem  Stock Price Down 0%
Verastem Stock Price Down 0%


© 2006-2018 Ticker Report. Google+.